HK1176552A1 - Method of treating prostate cancer with the gnrh antagonist degarelix gnrh - Google Patents

Method of treating prostate cancer with the gnrh antagonist degarelix gnrh

Info

Publication number
HK1176552A1
HK1176552A1 HK13103556.5A HK13103556A HK1176552A1 HK 1176552 A1 HK1176552 A1 HK 1176552A1 HK 13103556 A HK13103556 A HK 13103556A HK 1176552 A1 HK1176552 A1 HK 1176552A1
Authority
HK
Hong Kong
Prior art keywords
gnrh
prostate cancer
treating prostate
antagonist degarelix
degarelix
Prior art date
Application number
HK13103556.5A
Other languages
English (en)
Chinese (zh)
Inventor
Tine Kold Olesen
Bo-Eric Persson
Per Cantor
Meulen Egbert A Van Der
Jens-Christian Slott Jensen
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1176552(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HK1176552A1 publication Critical patent/HK1176552A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK13103556.5A 2008-02-11 2010-12-09 Method of treating prostate cancer with the gnrh antagonist degarelix gnrh HK1176552A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EP08250703 2008-02-29

Publications (1)

Publication Number Publication Date
HK1176552A1 true HK1176552A1 (en) 2013-08-02

Family

ID=39718285

Family Applications (4)

Application Number Title Priority Date Filing Date
HK10111506.2A HK1145011A1 (en) 2008-02-11 2010-12-09 Treatment of metastatic stage prostate cancer with degarelix
HK14103602.8A HK1190912A1 (en) 2008-02-11 2010-12-09 Treatment of metastatic stage prostate cancer with degarelix
HK13103556.5A HK1176552A1 (en) 2008-02-11 2010-12-09 Method of treating prostate cancer with the gnrh antagonist degarelix gnrh
HK14111736.0A HK1198243A1 (en) 2008-02-11 2010-12-09 METHOD OF TREATING PROSTATE CANCER WITH GNRH ANTAGONIST GnRH

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK10111506.2A HK1145011A1 (en) 2008-02-11 2010-12-09 Treatment of metastatic stage prostate cancer with degarelix
HK14103602.8A HK1190912A1 (en) 2008-02-11 2010-12-09 Treatment of metastatic stage prostate cancer with degarelix

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14111736.0A HK1198243A1 (en) 2008-02-11 2010-12-09 METHOD OF TREATING PROSTATE CANCER WITH GNRH ANTAGONIST GnRH

Country Status (25)

Country Link
US (15) US8841081B2 (xx)
EP (7) EP2249858A1 (xx)
JP (10) JP5924866B2 (xx)
KR (7) KR20220009504A (xx)
CN (4) CN101939020B (xx)
AU (2) AU2009213748B9 (xx)
BR (2) BRPI0908129A2 (xx)
CA (3) CA3235099A1 (xx)
CY (3) CY1115561T1 (xx)
DK (3) DK2650012T3 (xx)
EA (4) EA017582B1 (xx)
ES (3) ES2532709T3 (xx)
HK (4) HK1145011A1 (xx)
HR (3) HRP20140665T1 (xx)
IL (3) IL207295A (xx)
JO (1) JOP20090061B1 (xx)
MX (2) MX2010008816A (xx)
NZ (4) NZ587088A (xx)
PL (3) PL2650012T3 (xx)
PT (3) PT2650012E (xx)
RU (2) RU2504393C2 (xx)
SI (3) SI2650012T1 (xx)
TW (2) TWI442932B (xx)
WO (2) WO2009101533A1 (xx)
ZA (1) ZA201005697B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
BR112013023050A8 (pt) * 2011-03-09 2018-09-25 G Pestell Richard antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
CA2873743C (en) 2012-05-14 2022-12-06 Prostagene, Llc Using modulators of ccr5 for treating cancer
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
KR20220025231A (ko) 2012-09-26 2022-03-03 아라곤 파마슈티컬스, 인코포레이티드 비전이성 거세 저항성 전립선암 치료용 항안드로겐
JP6159870B2 (ja) 2013-03-15 2017-07-05 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物
US20140358576A1 (en) * 2013-05-15 2014-12-04 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
AU2015308987B2 (en) * 2014-08-26 2021-02-18 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
JP6941565B2 (ja) * 2015-05-12 2021-09-29 ドレクセル ユニバーシティ がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
US20200000872A1 (en) * 2017-01-30 2020-01-02 Antev Limited A composition comprising at least one gnrh antagonist
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN112261942A (zh) 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
CA3107597A1 (en) * 2018-08-01 2020-02-06 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE593491T1 (de) 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
EP0556034B2 (en) 1992-02-12 2004-07-21 Daikyo Gomu Seiko Ltd. A medical instrument
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5825730A (en) 1995-03-10 1998-10-20 Kabushiki Kaisha Toshiba Mastering machine having non-repetitive runout compensation
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
WO1999026964A1 (en) 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
ES2389627T3 (es) 1998-07-20 2012-10-29 Virbac (Australia) Pty Ltd Formulación para bioimplantes
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US7045605B2 (en) * 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
CN100509053C (zh) 2002-09-27 2009-07-08 赞塔里斯有限公司 持续释放的药物活性肽施用形式及其制备方法
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
KR20100120289A (ko) 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
WO2009102720A1 (en) * 2008-02-11 2009-08-20 Safety Syringes, Inc. Reconstitution means for safety device
SG175744A1 (en) 2009-04-24 2011-12-29 Polypeptide Laboratories As Method for the manufacture of degarelix
EP2424503B1 (en) 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
PL2731607T3 (pl) 2011-07-15 2018-03-30 Ferring B.V. Sposób koordynacji czasu kolonoskopii, w którym podaje się kompozycję pikosiarczanową
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix

Also Published As

Publication number Publication date
EA201300742A1 (ru) 2014-02-28
BRPI0908129A2 (pt) 2015-08-04
DK2249859T3 (da) 2014-06-02
ES2479441T3 (es) 2014-07-24
SI2505204T1 (sl) 2015-04-30
EP2799085A1 (en) 2014-11-05
US10695398B2 (en) 2020-06-30
JP6189234B2 (ja) 2017-08-30
RU2010133481A (ru) 2012-03-20
EA201300741A1 (ru) 2014-02-28
US9579359B2 (en) 2017-02-28
US20140113870A1 (en) 2014-04-24
EP4257197A3 (en) 2023-11-29
JP2022184898A (ja) 2022-12-13
EP2249858A1 (en) 2010-11-17
CA2714445A1 (en) 2009-08-20
US20090203623A1 (en) 2009-08-13
US20220323538A1 (en) 2022-10-13
US20220031801A1 (en) 2022-02-03
EP2650012A1 (en) 2013-10-16
WO2009101530A1 (en) 2009-08-20
JP2011511786A (ja) 2011-04-14
EP3360565A1 (en) 2018-08-15
BRPI0908127A2 (pt) 2015-08-04
ES2540235T3 (es) 2015-07-09
ES2532709T3 (es) 2015-03-31
RU2504394C2 (ru) 2014-01-20
EP2650012B1 (en) 2015-03-25
DK2505204T3 (da) 2015-03-16
JOP20090061B1 (ar) 2021-08-17
JP2016216455A (ja) 2016-12-22
US11826397B2 (en) 2023-11-28
EA017582B1 (ru) 2013-01-30
KR20140130757A (ko) 2014-11-11
KR20180118830A (ko) 2018-10-31
EA036695B1 (ru) 2020-12-09
JP2018039814A (ja) 2018-03-15
EP2249859B1 (en) 2014-04-23
KR20100126362A (ko) 2010-12-01
IL223124A0 (en) 2012-12-31
PT2505204E (pt) 2015-03-26
US20140349935A1 (en) 2014-11-27
JP2022133426A (ja) 2022-09-13
TWI539959B (zh) 2016-07-01
JP2024028869A (ja) 2024-03-05
PL2650012T3 (pl) 2015-08-31
CA3235099A1 (en) 2009-08-20
RU2504393C2 (ru) 2014-01-20
MX2010008816A (es) 2010-09-07
US9877999B2 (en) 2018-01-30
CA2714445C (en) 2018-01-16
MX2010008817A (es) 2010-09-09
US11766468B2 (en) 2023-09-26
CY1116289T1 (el) 2017-02-08
JP2011511785A (ja) 2011-04-14
CN101939020A (zh) 2011-01-05
JP6618967B2 (ja) 2019-12-11
JP5876652B2 (ja) 2016-03-02
US20220226422A1 (en) 2022-07-21
CY1115561T1 (el) 2017-01-04
US20130029910A1 (en) 2013-01-31
HK1198243A1 (en) 2015-03-20
JP7400029B2 (ja) 2023-12-18
NZ587057A (en) 2012-12-21
KR20230088848A (ko) 2023-06-20
AU2009213751B2 (en) 2014-09-25
CN107412726A (zh) 2017-12-01
EA026521B1 (ru) 2017-04-28
DK2650012T3 (da) 2015-06-15
EA020543B1 (ru) 2014-12-30
SI2249859T1 (sl) 2014-08-29
US10729739B2 (en) 2020-08-04
US20220218782A1 (en) 2022-07-14
JP2014141505A (ja) 2014-08-07
CA2714444A1 (en) 2009-08-20
ZA201005697B (en) 2014-01-24
AU2009213751A1 (en) 2009-08-20
TW200938218A (en) 2009-09-16
CN103990107A (zh) 2014-08-20
EP2505204B1 (en) 2014-12-24
US20200237854A1 (en) 2020-07-30
TWI442932B (zh) 2014-07-01
KR20220009504A (ko) 2022-01-24
CN101998861A (zh) 2011-03-30
HRP20150633T1 (hr) 2015-07-31
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
EA200901075A1 (ru) 2010-04-30
AU2009213748B9 (en) 2014-05-22
KR20100123714A (ko) 2010-11-24
AU2009213748B2 (en) 2014-03-13
EP2505204A2 (en) 2012-10-03
US8841081B2 (en) 2014-09-23
JP5924866B2 (ja) 2016-05-25
EP2249859A1 (en) 2010-11-17
US20220218783A1 (en) 2022-07-14
JP2014167009A (ja) 2014-09-11
IL207400A (en) 2014-12-31
NZ603932A (en) 2014-04-30
JP6254042B2 (ja) 2017-12-27
CN101939020B (zh) 2012-12-26
PT2249859E (pt) 2014-07-31
US10973870B2 (en) 2021-04-13
NZ603958A (en) 2013-03-28
US9415085B2 (en) 2016-08-16
HRP20140665T1 (hr) 2014-10-10
IL207295A (en) 2015-03-31
RU2010133480A (ru) 2012-03-20
KR20150091543A (ko) 2015-08-11
HK1145011A1 (en) 2011-03-25
IL207400A0 (en) 2010-12-30
PL2249859T3 (pl) 2014-10-31
WO2009101533A1 (en) 2009-08-20
NZ587088A (en) 2012-12-21
US20090203622A1 (en) 2009-08-13
TW200938217A (en) 2009-09-16
AU2009213748A1 (en) 2009-08-20
US20190167755A1 (en) 2019-06-06
HRP20150290T1 (hr) 2015-04-10
US20210128673A1 (en) 2021-05-06
US20170035833A1 (en) 2017-02-09
JP2016193910A (ja) 2016-11-17
EP2505204A3 (en) 2013-01-09
EA200901074A1 (ru) 2010-04-30
KR101542480B1 (ko) 2015-08-07
CY1116341T1 (el) 2017-02-08
SI2650012T1 (sl) 2015-06-30
IL207295A0 (en) 2010-12-30
US20170290879A1 (en) 2017-10-12
PL2505204T3 (pl) 2015-05-29
PT2650012E (pt) 2015-06-30

Similar Documents

Publication Publication Date Title
IL223124A0 (en) Method of treating prostate cancer with the gnrh antagonist degarelix
IL313131A (en) Molecular characterization of tumors
IL218987A0 (en) Methods and compositions for treating cancer
EP2310006A4 (en) TREATMENT OF CANCER
EP2461814A4 (en) PROSTATE CANCER TREATMENT
ZA201107879B (en) Composition for the treatment of prostate cancer
EP2367939A4 (en) METHODS FOR THE DIAGNOSIS OR TREATMENT OF PROSTATE CANCER
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
GB0820309D0 (en) Detection of cancer
EP2303304A4 (en) METHOD FOR THE TREATMENT OF CANCER WITH APOE PEPTIDES
GB0804496D0 (en) Treating cancer
EP2345415A4 (en) THERAPEUTIC / PROPHYLACTIC AGENT FOR PROSTATE CANCER
IL218230A0 (en) Method of treating cancer
ZA201109508B (en) Methods of using corticotropin-releasing factor for the treatment of cancer
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
EP2560639A4 (en) METHOD FOR THE TREATMENT OF PROSTATE CANCER
EP2409156A4 (en) AKT TYROSINE 176 PHOSPHORYLATION BIOMARKER FOR CANCER
HK1258957A1 (zh) 用地加瑞克治療轉移階段前列腺癌
IL196361A0 (en) Combination methods of treating cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190210